Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17571444 | 1.00 | TRPA1 (0.44) | TRPA1L3MBTL1MAPK1PTK2TDP1 | |
| SCHEMBL17571385 | 0.84 | TSHR (0.43) | TRPA1L3MBTL1MAPK1PTK2TDP1 | |
| SCHEMBL17559576 | 0.83 | HCAR3 (0.46) | L3MBTL1MAPK1PTK2TDP1TSHR | |
| SCHEMBL17559599 | 0.75 | CYP11B1 (0.41) | TDP1NPC1RAB9AMAPT | |
| SCHEMBL17559597 | 0.75 | CYP11B1 (0.41) | TDP1NPC1RAB9AMAPT | |
| SCHEMBL17559684 | 0.74 | F10 (0.42) | TDP1NPC1RAB9ANPSR1 | |
| SCHEMBL17571431 | 0.74 | F10 (0.42) | TDP1NPC1RAB9ANPSR1 | |
| SCHEMBL19435378 | 0.74 | F10 (0.42) | TDP1NPC1RAB9ANPSR1 | |
| SCHEMBL18286138 | 0.73 | PTK2 (0.49) | TRPA1L3MBTL1MAPK1PTK2TDP1 | |
| SCHEMBL17571384 | 0.73 | TRPA1 (0.51) | TRPA1L3MBTL1MAPK1PTK2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024509-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | C4X DISCOVERY LIMITED (GB) | 2024-07-02 | — | — | US | disclosed |
| US-10611760-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | C4X DISCOVERY LIMITED (GB) | 2020-04-07 | — | — | US | disclosed |
| US-20170291897-A1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | INDIVIOR INC. | 2017-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024509-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | HCRTR1, HCRTR2, NPY1R | TRPA1 538/4885L3MBTL1 4730/4885MAPK1 705/4885 |
| US-10611760-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | HCRTR1, HCRTR2, NPY1R | TRPA1 538/4885L3MBTL1 4730/4885MAPK1 705/4885 |
| US-20170291897-A1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | HCRTR1, HCRTR2, NPY1R | TRPA1 538/4885L3MBTL1 4730/4885MAPK1 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.